61 results about "Pancreatic tissue" patented technology

The invention belongs to the field of biological medicines, and discloses application of flufenidone in preparation of a medicine for treating pancreatic diseases. Researches find that the flufenidone can improve serum amylase and lipase levels of an acute pancreatitis model mouse, and can improve pancreatic tissue edema, necrosis and inflammatory cell infiltration of the acute pancreatitis model mouse; the traditional Chinese medicine composition can improve acute pancreatitis model mouse lung tissue alveolar interval thickening and inflammatory cell infiltration, and provides guarantee for application of the traditional Chinese medicine composition in preparation of drugs for treating pancreatic diseases.

The invention discloses an application of astaxanthin in preparation of a regulator for improving the gentisic acid level. On the basis of non-targeted metabonomics analysis, it is found for the first time that in the SAP pathogenesis process, the level of a flora metabolite, namely gentisic acid (GA), in intestinal contents is remarkably reduced, and in-vivo gentisic acid level can be remarkably callback through astaxanthin intervention. Further research proves that exogenous supplement of gentisic acid can effectively simulate the protection effect of astaxanthin, including improvement of pancreatic tissue pathological damage, reduction of serum lipase and amylase activity, and inhibition of systemic inflammatory response (down-regulation of IL-1beta, IL-6 and TNF-alpha and up-regulation of IL-10). The invention not only discloses a new mechanism that astaxanthin plays a therapeutic role through an'intestinal flora-metabolite 'axis, but also determines that gentisic acid is used as a novel drug target for treating SAP, and constructs a new method for screening drugs for treating SAP according to the novel drug target.

The present application relates to a deoxyribonuclease mutant and its application in preparing PDRN. The amino acid sequence of the deoxyribonuclease mutant is shown as SEQ ID NO. 1, and the nucleotide sequence of the encoding gene is shown as SEQ ID NO. 2. The present application also provides the application of the deoxyribonuclease mutant and / or the encoding gene of the deoxyribonuclease mutant in preparing PDRN, and the specific application method. The present application is based on the deoxyribonuclease expressed by the DNASE1 gene of bovine pancreas tissue, and the amino acids at positions 69, 132 and 215 are selected for iterative saturation mutation. Compared with the wild-type enzyme, the enzyme activity of the deoxyribonuclease mutant A69H-S132R-Q215C is increased by 2.15 times, reaching 4.1x10 6 U / mL, and the DNA extraction rate of salmon PDRN prepared by using the mutant enzyme prepared by the present application is 15.2%, the DNA content is 99.1%, and the molecular weight is 1.05 million Daltons, which is significantly improved compared with the wild-type enzyme, and the PDRN in this molecular weight range has more significant biological activity.

The invention discloses a preparation rich in polygonatum sibiricum polypeptide and application of the preparation in diabetes mellitus. The composition is prepared from rhizoma polygonati polypeptide, semeglutide, astaxanthin, an active agent and a ferroptosis mixture. Pharmacodynamic experiments show that in a diabetic mouse model, fasting blood glucose can be remarkably reduced, the serum insulin level can be increased, renal function indexes can be improved, and expression of NLRP3 inflammation pathway related proteins (NLRP3, Caspase-1 and IL-1beta) in pancreatic tissue can be remarkably inhibited. By integrating multiple mechanisms of blood glucose reduction, oxidation resistance, inflammation resistance, ferroptosis resistance and the like, multi-target collaborative intervention is realized, the pharmaceutical composition is remarkably superior to a single component in the aspects of blood glucose reduction, pancreas islet function protection and complication alleviation, and a new clinical strategy is provided for treatment of diabetes mellitus, especially type 1 diabetes mellitus.

The invention discloses a Ruditapes philippinarum miR-263b inhibitor and application thereof, and finds that Ruditapes philippinarum miR-263b can regulate and control innate immune response of a host by targeting RpSC2, negatively regulates activation of an immune-related signal channel in a vibrio infection process, and further, on the basis of a molecular regulation and control mechanism, the Ruditapes philippinarum miR-263b inhibitor can be used for inhibiting the infection of vibrio. The invention discloses a specific inhibitor which is completely complementary with a miR-263b mature body sequence. Experimental data show that after Ruditapes philippinarum is injected with the miR-263b inhibitor, the expression level of miR-263b in vivo is reduced, and the inhibition effect of miR-263b on RpSC2 is effectively relieved, so that the expression level of a target gene RpSC2 is up-regulated, an NF-kappa B immune signal channel is activated, the immune defense capability of the Ruditapes philippinarum on vibrio anguillarum is enhanced, the death rate after infection is remarkably reduced, and the Ruditapes philippinarum is prevented from being infected. The in-vivo bacterium loading amount is obviously reduced, and the pathological injury of hepatopancreas tissue is obviously relieved.

Systems and methods are provided for delivering a therapeutic treatment to a target population of cells (including, but not limited to, tumors, eyeballs, pancreatic tissue, liver tissue, and lung tissue) in a subject. The system includes an injectable aqueous solution in a vial enclosed with a septum. The solution comprises particles containing a therapeutic agent and having a coating surrounding the therapeutic agent, the coating comprising chitosan to provide controlled release of the agent from the particles. The solution also comprises a chitosan polymer in the form of a polymer gel matrix, further providing controlled release of the particles from the aqueous gel environment. There is also provided a method of making a freeze-dried powder placed in a vial containing a chitosan polymer and chitosan-coated particles, the powder when mixed with water forming the above injectable aqueous solution with particles and chitosan gel.

The invention provides an application of dimethyl fumarate in preparation of a medicine for treating hypertriglyceridemia type acute pancreatitis. Experiments prove that the dimethyl fumarate can treat the hypertriglyceridemia acute pancreatitis, and specifically, the dimethyl fumarate can relieve pancreatic tissue edema of the hypertriglyceridemia acute pancreatitis, relieve pancreatitis infiltration, relieve pancreatic acinus necrosis and the like. The invention provides a new strategy for treating hypertriglyceridemia acute pancreatitis, and has a good clinical application prospect.

The invention discloses a probiotic agent for relieving prediabetic action and application thereof, and belongs to the technical field of microorganisms. Experiments prove that bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics can relieve the prediabetic stage, which is specifically embodied in reducing weight gain of mice in the prediabetic stage, regulating blood sugar metabolism, improving sugar tolerance and insulin resistance, protecting liver and pancreas tissues, being beneficial to increasing the diversity of intestinal flora, recovering the structure of the intestinal flora, and improving the immunity of the mice in the prediabetic stage. The invention also provides a preparation method of the bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. The bifidobacterium longum CCFM1113 and bifidobacterium adolescentis CCFM1386 composite probiotics. And the growth of beneficial bacteria related to metabolic disorder is enriched and regulated. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

The invention relates to the technical field of novel application of compounds, in particular to novel application of meclozine and analogues thereof. The invention relates to an application of at least one of meclozine and analogues thereof or pharmaceutically acceptable salts or esters thereof in preparation of drugs for preventing and / or treating pancreatitis. The meclozine and the analogue thereof can obviously improve pancreatic tissue necrosis, inflammatory response and oxidative stress of pancreatitis, inhibit alveolar cell death and improve lung injury caused by pancreatitis, so that the meclozine and the analogue thereof can be used as a medicine for treating pancreatitis.

The invention discloses highly acetylated glucomannan and application thereof in preparation of a product with an effect of relieving prediabetes mellitus, and belongs to the technical field of medicines. In-vivo experiments prove that the glucomannan with high acetylation degree has the effect of relieving the prediabetic stage, which is specifically reflected in weight gain of mice in the prediabetic stage, regulation of blood glucose metabolism, improvement of glucose tolerance and insulin resistance, regulation of blood lipid metabolism, protection of liver and pancreatic tissues and reduction of epididymal fat cell size. The invention provides an important basis for developing a dietary formula suitable for prediabetic patients, and provides a new method for prevention and management of diabetes mellitus.

To provide various compositions and methods useful for the treatment of pancreatic cancer, such as pancreatic ductal adenocarcinoma (PDAC), and methods for activating pancreatic tissue-specific anti-tumor T cell immunity.SOLUTION: In certain embodiments, such methods comprise administration of IL33. In certain embodiments, such methods comprise administration of PD-1 and / or PD - L1 inhibitors.SELECTED DRAWING: None

This invention belongs to the field of biomedical technology and discloses the application of NP in the preparation of a glycemic regulator for aging type 2 diabetes. The NP is a nanoscale complex formed by hydrogen bonding of turtle egg peptide with a molecular weight less than 3 kDa and naringenin at a mass ratio of 100:1. The formulation promotes liver glycogen synthesis and repairs pancreatic tissue structure and pancreatic β-cell function by activating the hepatic IRS1 / PI3K / AKT / GSK-3β signaling pathway and upregulating GLUT2 protein expression. The NP provided by this invention can significantly reduce fasting blood glucose levels in aging type 2 diabetic mice, improve oral glucose tolerance, and reduce the area under the blood glucose curve. Simultaneously, by restoring insulin signal transduction, it significantly reduces the insulin resistance index and improves the insulin sensitivity index, with an improvement level approaching that of the classic hypoglycemic drug metformin.

The invention belongs to the field of pancreatic duct adenocarcinoma prediction, and provides a pancreatic duct adenocarcinoma prediction method and system based on oral flora. The pancreatic ductal adenocarcinoma prediction method based on oral flora comprises the following steps: acquiring relative abundance information of each biomarker in a potential biomarker set for diagnosing pancreatic ductal adenocarcinoma of a to-be-detected person; using the relative abundance information of each biomarker in the biomarker set and a pre-trained multivariate statistical model to obtain a probability value of suffering from pancreatic ductal adenocarcinoma; the method comprises the following steps: performing microbiome difference analysis on saliva, duodenal juice and pancreatic tissue samples of a pancreatic ductal adenocarcinoma patient group and a pancreatic benign disease patient group, and taking an intersection of differential bacteria in the samples to obtain a potential biomarker set for diagnosing the pancreatic ductal adenocarcinoma.

The invention discloses application of pancreatic protein peptide in preparation of products for improving insulin resistance and repairing pancreatic functions, and relates to the technical field of biological medicines. The pancreatic-derived protein peptide is extracted and purified from porcine pancreatic tissue through a specific enzymolysis process, the molecular weight is concentrated at 800-2000Da, and the pancreatic-derived protein peptide contains 12 essential amino acids. Experiments prove that the protein peptide can significantly improve insulin sensitivity and promote pancreatic beta cell proliferation through oral administration or intraperitoneal injection, and has no obvious toxic or side effect. The invention provides a novel treatment means for diseases related to type 2 diabetes and pancreatic function impairment, and has a wide clinical application prospect.

Disclosed herein are hepato-biliary-pancreatic organoid (“HBPO” or “HBP organoid”) compositions, and methods of making and using hepato-biliary-pancreatic organoid compositions. The disclosed compositions may have two or more functions selected from hepatic tissue function, biliary tissue function, exocrine pancreatic function, and endocrine pancreatic tissue function. Methods of treating individuals using the hepato-biliary-pancreatic organoid compositions is also disclosed.

To provide systems and methods for delivering a therapeutic treatment to a targeted population of cells of a subject.SOLUTION: The system includes an injectable aqueous solution in a vial enclosed with a septum. The injectable aqueous solution is formulated for injection into a targeted cell population. The solution includes particles containing a therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan so as to provide controlled release of the agent from the particles. The solution further includes chitosan polymer in a form of a polymer gel matrix, further providing controlled release of the particles from the aqueous gel environment. Also provided are methods of manufacturing a lyophilized powder disposed within a vial containing chitosan polymer and chitosan coated particles, the powder forming the above-described injectable aqueous solution of particles and chitosan gel upon mixing with water. Also provided are methods of injecting the above-described injectable aqueous solution into a targeted population of cells, including but not limited to tumors, eyeballs, pancreatic tissue, liver tissue, and lung tissue, in order to provide localized delivery of a therapeutic agent.SELECTED DRAWING: Figure 12

The invention discloses an application of sgRNA targeting PGAM5 in acute pancreatitis as well as a product and a gene therapy drug of the sgRNA. In-vivo experiments prove that the PGAM5-targeted sgRNA can significantly inhibit PGAM5 gene expression, reduce pancreatic tissue inflammatory cell infiltration and reduce serum lipase and amylase levels, thereby blocking generation and development of AP. According to the invention, the targeted knockout of the PGAM5 gene by using the CRISPR-Cas9 system is proposed for the first time, and a new strategy is provided for the gene therapy of AP.

The present disclosure relates to a medical tissue adhesive for pancreatic plugging and the preparation method and use thereof. The medical tissue adhesive composition forming the medical tissue adhesive of the present disclosure comprises a medical tissue adhesive component and a chelating agent component; wherein the medical tissue adhesive component comprises a first component and a second component, the first component comprises four-arm polyethylene glycol amine, and the second component comprises four-arm-polyethylene glycol-succinimidyl glutarate; wherein m and n are natural numbers; and the chelating agent component comprises polyphenol. The medical tissue adhesive prepared from the medical tissue adhesive composition of the present disclosure is capable of firmly binding to the surface of the pancreatic tissue, and is capable of withstanding the dynamic pressure as a result of pancreatic juice leakage and the enzymatic degradation activity of pancreatic juice. More importantly, the medical tissue adhesive of the present disclosure has an excellent antibacterial ability and is capable of preventing the infection caused by the long-term accumulation of the leaked pancreatic juice.

Methods of using pulsed focused ultrasound (pFUS) therapy to treat pancreatic disorders such as type 1 diabetes, pancreatitis, and pancreatic cancer are provided. The methods utilize pulsed focused ultrasound (pFUS) therapy either by itself or in combination with islet transplantation and / or stem cell therapy to promote regeneration of damaged pancreatic tissue, increase insulin secretion in response to glucose, or improve engraftment and revascularization of transplanted islets or beta cells. Additionally, methods of using pFUS are provided for modulating paracrine secretion in the pancreas, islets, beta cells, or stem cells, or at a transplantation site to therapeutically alter levels of various factors including, without limitation, cytokines, growth factors, angiogenic factors, and cell adhesion molecules.

The invention relates to application of indole-3-lactic acid in preparation of an acute pancreatitis resisting medicine, and belongs to the technical field of medicines. The invention provides an application of indole-3-lactic acid in preparation of an acute pancreatitis resisting medicine. An antibiotic mixture is used for conducting intragastric administration on a mouse, intestinal bacteria are removed, ILA and STS are subjected to intragastric administration on the mouse, leptofrog and arginine are injected into the abdominal cavity of the mouse for acute pancreatitis modeling, the acute pancreatitis resisting effect of ILA is studied, and the result shows that the amylase concentration in serum of the mouse subjected to intragastric administration of ILA is remarkably reduced; compared with STS, the ILA has the advantages that pancreatic tissue alveolar cell damage and inflammatory infiltration are obviously reduced, inflammatory cytokines in pancreatic tissue and serum are obviously reduced, and compared with STS, the ILA has a better protection effect, so that the ILA has the effect of resisting acute pancreatitis, and a new treatment way is provided for preventing and treating acute pancreatitis.

Use of muparfostat in preparing a medicament for treating non-functional pancreatic neuroendocrine tumors or exocrine pancreatic cancer. A pharmaceutical composition comprising muparfostat, which is for use in the treatment of non-functional pancreatic neuroendocrine tumors or exocrine pancreatic cancer. The pharmaceutical composition further comprises one or more additional antitumor drugs, such as chemotherapeutic drugs. The medicament or the pharmaceutical composition can reduce pancreatic tissue fibrosis in pancreatic cancer patients, thereby effectively treating pancreatic cancer.

The present invention belongs to the field of biomedicine, and in particular relates to CD53 as a biomarker for the diagnosis and prognosis of acute pancreatitis, CD53 neutralizing antibodies and their applications. The present invention's research confirms the key role of CD53 expression levels in acute pancreatitis. It is the first time that CD53 has been found to be a marker for acute pancreatitis and is associated with the prognosis of patients with acute pancreatitis. Therefore, it can be used as a biomarker for the diagnosis and prognosis of acute pancreatitis. The present invention's research confirms that CD53 neutralizing antibodies can significantly reduce inflammatory damage and NETs formation in pancreatic tissue in mice. CD53 is expected to be developed as an effective biomarker for early diagnosis or prognosis of acute pancreatitis, and CD53 neutralizing antibodies can be used as an effective drug for the prevention or treatment of acute pancreatitis.

The invention discloses an efficient universal mouse pancreatic tissue single-cell suspension preparation method, and belongs to the technical field of cell biology. Pancreas are rich in digestive enzymes, so that the treatment difficulty of in-vitro cells is high, and a high-quality single-cell suspension is difficult to prepare by a traditional method. The method comprises the steps of reagent preparation, tissue sampling, tissue dissociation, red cracking and cleaning, AOPI dyeing quality inspection and the like. Components and concentrations of a tissue enzymatic hydrolysate, a cell cleaning solution and a cell suspension are determined in reagent preparation; the acquisition method of the pancreatic tissue of the mouse is defined by tissue sampling; the tissue dissociation adopts a two-round digestion mode, and the cut tissue is subjected to enzymolysis by using a compound enzyme solution under specific conditions; the cell precipitates are treated through red cracking and cleaning; aOPI dyeing quality inspection is used for analyzing cell count and motility rate. According to the method, the culture medium containing specific components and the compound enzyme liquid are creatively used, the problem that pancreas single cells are difficult to dissociate can be effectively solved, the single-cell suspension with high motility rate, high purity and low adhesion is obtained, and the requirements of downstream single-cell experiments are met.

The invention discloses an application of (1S, 2S, 4R)-1-methyl-2, 4-bis (prop-1-ene-2-yl)-1-vinylcyclohexane (alias, beta-elemene) in preparation of a medicine, and the medicine is used for treating or preventing diseases related to acute inflammation, such as acute inflammation, acute inflammation, acute inflammation, acute inflammation and acute inflammation. Comprise acute lung injury related to sepsis caused by lipopolysaccharide (LPS), acute edema pancreatitis induced by ceratidine and severe necrotizing pancreatitis induced by L-arginine, but are not limited to the inducers, and specifically, the inducers can be used for inducing acute lung injury related to sepsis caused by lipopolysaccharide (LPS), acute edema pancreatitis induced by ceratidine and severe necrotizing pancreatitis induced by L-arginine. The medicine can inhibit or improve pathological injury and inflammatory response of lung tissue and pancreatic tissue of acute lung injury and acute pancreatitis.

The invention relates to the technical field of medical image processing, in particular to a pancreas focus tissue segmentation method and system based on multi-target recognition, and the method comprises the following steps: obtaining a pancreas tissue CT image; extracting a foreground region from the pancreatic tissue CT image, and performing classification identification on the foreground region through a pre-established classification model to obtain an attribute category of the foreground region; and according to the U-Net network corresponding to the attribute category of the foreground region, performing target segmentation on the foreground region to obtain a multi-target segmentation result of the pancreatic tissue. According to the method, through extraction and classification identification of the foreground regions, the corresponding intra-tumor tissue and peritumor tissue segmentation process is carried out on the foreground regions of the corresponding categories, interference of other regions is avoided, and the segmentation efficiency and segmentation precision of the intra-tumor region and the peritumor region are improved.

The invention relates to the technical field of preparation methods of exosomes, and discloses a preparation method and application of a rhubarb exosome. According to the scheme, the purity of the rhubarb exosome is remarkably improved by combining gradient centrifugation with a density gradient centrifugation technology, a novel nano delivery system is developed by utilizing the overall medicinal components of the traditional Chinese medicine rhubarb, and the limitation of traditional Chinese medicine monomer component research is broken through; the prepared exosome shows efficient pancreatic targeting in a severe acute pancreatitis model, pancreatic tissue pathological damage, inflammatory factor level and serum enzyme activity can be remarkably reduced, meanwhile, the advantage of synergistic effect of multiple components of traditional Chinese medicine is reserved, and a new strategy is provided for improving the bioavailability of the traditional Chinese medicine and innovating traditional Chinese medicine dosage forms.

The invention provides application of a lucid ganoderma extract tablet in a product for treating type 2 diabetes mellitus, and the lucid ganoderma extract tablet can obviously increase the weight of a mouse, obviously reduce the increase of blood glucose of a T2DM mouse, effectively relieve impaired glucose tolerance of the T2DM mouse, effectively relieve dyslipidemia of the T2DM mouse and relieve the insulin resistance state of the T2DM mouse. Pancreatic tissue damage can be remarkably improved, and the effect of a dose group in the ganoderma lucidum extract tablet is most remarkable, so that the ganoderma lucidum extract tablet has the effect of treating type 2 diabetes mellitus.

The invention belongs to the technical field of biology, and particularly relates to an efficient extraction method and application of pancreatic tissue RNA. The extraction method comprises the following steps: pre-cooling the grinding appliance; tissue grinding: shearing a pancreatic tissue sample, rapidly putting a trypsin inhibitor ulinastatin into a pre-cooled grinding appliance, shearing and grinding, and supplementing liquid nitrogen at any time in the grinding process until the tissue becomes powder; splitting decomposition: adding a splitting decomposition solution into the ground tissue for splitting decomposition, transferring to an EP centrifugal tube, cooling on dry ice, and separating RNA through vortex and low-temperature high-speed centrifugation steps; rNA purification: adding chloroform and ethanol in a uniform dry ice working environment, and combining low-temperature high-speed centrifugation and filtration to further purify RNA; and RNA elution and storage: eluting the purified RNA into enzyme-free water, and carrying out concentration and purity determination. By adopting the method, the RNA extraction quality can be remarkably improved, the degradation risk of the RNA in the extraction process can be remarkably reduced, and the integrity and purity of the RNA can be remarkably improved.

The application discloses a duck hepatitis virus 1 type DHAV-1 / HNSQ and application thereof, and belongs to the field of animal virology and genetic engineering. The duck hepatitis virus 1 type DHAV-1 / HNSQ has been preserved in the China Center for Type Culture Collection on March 5, 2026, and the preservation number is CCTCC NO:V202622. The VP1 gene of the variant strain has a deletion of three consecutive nucleotides. Animal experiments show that, after the variant strain infects ducklings, in addition to causing typical duck viral hepatitis lesions, the variant strain can also stably cause a new phenotype, such as thinning of the heart wall, reduction of myocardial toughness and liquefaction necrosis of pancreatic tissue, which has never been reported in the prior art, thereby providing important biological materials for effective prevention and control of duck hepatitis and pathogenic mechanism research.